What is the Impact of Implementing Pharmaceutical Algorithms in the PharmaClass® Software, on the Handling the Patient's Medication Load, by the Clinical Pharmacist?

Pharmacist-Patient Relations Clinical Trial

Official title:

What is the Impact of Implementing Pharmaceutical Algorithms in the PharmaClass® Software, on the Handling the Patient's Medication Load, by the Clinical Pharmacist? Analysis of These Impacts Within 2 Geriatric Units of the CHU Brugmann Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05416892
• Other study ID #: CHUB-PharmaClass
• Status: Completed
• Start date: September 14, 2021
• Est. completion date: April 1, 2022

Study information

• Verified date: June 2022
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The clinical pharmacists present in the hospitalisation units aim to ensure the daily review of the drug prescriptions of hospitalized patients. In order to optimize their work, the objective of this study would be to provide them with a clinical decision support tool via artificial intelligence in order to improve the patient's medication management. This study will test the Pharmaclass® software.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: April 1, 2022
• Est. primary completion date: April 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Hospitalized patient entering the SU06 or SU13 geriatrics unit of the Paul Brien site of the CHU Brugmann Hospital between November 16 2021 and April 15, 2022
• Speaking French and/or Dutch
• With chronic renal failure or taking at least one medicine for diabetes, heart, COPD, asthma, high blood pressure, epilepsy, atrial fibrillation, osteoporosis, high cholesterol, pain, parkinsonism, blood clotting, constipation, thyroid, depression, benign prostatic hypertrophy, gastric ulcer, Alzheimer's disease, cirrhosis as well as for electrolyte disorders (hypo or hypernatremia / potassium / calcium/magnesemia/phosphatemia).

Exclusion Criteria:

• Patient who died or was transferred to another care unit during his/her hospitalization

Related Conditions & MeSH terms

• Pharmacist-Patient Relations

Intervention

Other:
• Pharmaclass® software
Clinical decision support tool via artificial intelligence in order to improve the patient's medication management.

Locations

Country	Name	City	State
Belgium	Brugmann university hospital	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Murielle Surquin

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time	Time required to perform an intervention (pharmacist versus software)	5 months
Primary	Dosage compliance	Dosage compliance with existing recommendations and laboratory results/clinical parameters (pharmacist versus software)	5 months
Primary	Medication error severity	Severity of the medication error that could be avoided (pharmacist versus software)	5 months
Primary	Geriatrician approval	Number of interventions validated/refused by the geriatrician (pharmacist versus software)	5 months